COPD Biomarker Qualification Consortium (CBQC)
At a Glance
- Status: Active Consortium
- Year Launched: 2011
- Initiating Organization: COPD Foundation
- Initiator Type: Nonprofit foundation
- Disease focus:
- Location: North America
The COPD Biomarker Qualification Consortium (CBQC) pools data related to biomarkers from many clinical trials conducted by pharmaceutical companies, academia, and the National Heart, Lung, and Blood Institute to create a sufficiently large data set to allow for evidence that supports qualification by the U.S. Food and Drug Administration and the European Medicines Agency. CBQC is considering a range of biomarkers that measure quality of life, exercise capacity, specific measures of lung function (such as hyperinflation), and blood tests that report inflammation in chronic obstructive pulmonary disease (COPD).
CBQC’s mission is to qualify biomarkers for COPD to provide measures that could facilitate the development of new treatments.
2011: CBQC created as a result of COPD Biomarker Qualification Workshop.
The results of the biomarker qualification will be made public; however, the database will not be made public to protect patient information. The database will be available to regulatory authorities.
Sponsors & Partners